Therapeutic approach of cannabidiol on neurodegenerative diseases: evaluation of the effects on the progression of these diseases and their symptoms
DOI:
https://doi.org/10.33448/rsd-v11i8.31515Keywords:
Cannabidiol; Cannabidiol signaling; Neurodegenerative diseases; Treatment.Abstract
Several neurodegenerative diseases current therapies, such as for Parkinson’s disease, Alzheimer’s disease and Multiple Sclerosis, need constant improvement, aiming to enhance quality of life, symptomatic improvement, and possibly recovery. Thus, this integrative literature review aims to understand how Cannabidiol (CBD) can be used in the treatment of neurodegenerative diseases, analyzing applicability, therapeutic effects and the method in which this substance is used as this medicinal form. From a search in PubMed, VHL and LILACS databases, articles in English were selected, published between the years 2016 and 2021, which addressed the subject and delved into the effects of CBD on neurodegenerative diseases, specifically: Parkinson's Disease, Multiple Sclerosis, Tuberous Sclerosis, Alzheimer's Disease and Huntington's Disease. After performing the integrative analysis, it was concluded that CBD is a neuroprotective and anti-inflammatory agent, acting to improve motor performance, decrease pain and spasticity. Therefore, it is possible to conclude that, although more studies are needed about its effects and therapeutic mechanisms, cannabidiol is a viable and beneficial substance for use in new therapies for neurodegenerative diseases.
References
Abate, G., Uberti, D., & Tambaro, S. (2021) Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy. Biology, 10(6), 542. https://doi.org/10.3390/biology10060542
Almeida, C. de, Brito, M., Bosaipo, N. B., Pimentel, A. V., Tumas, V., Zuardi, A. W., Crippa, J., Hallak, J., & Eckeli, A. L. (2021). Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Movement Disorders, 36(7), 1711–1715. https://doi.org/10.1002/mds.28577
Burgaz, S., García, C., Gómez-Cañas, M., Rolland, A., Muñoz, E., & Fernández-Ruiz, J. (2021). Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease. Molecules, 26(11), 3245. https://doi.org/10.3390/molecules26113245
Cassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G. (2020). From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases. Frontiers in Pharmacology, 11, Article 124. https://doi.org/10.3389/fphar.2020.00124
Chiricosta, L., Silvestro, S., Pizzicannella, J., Diomede, F., Bramanti, P., Trubiani, O., & Mazzon, E. (2019). Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. International Journal of Molecular Sciences, 20(23), 6039. https://doi.org/10.3390/ijms20236039
Faria, S. M., Fabrício, D. M., Tumas, V., Castro, P. C., Ponti, M. A., Hallak, J. E., Zuardi, A. W., Crippa, J. A. S., & Chagas, M. H. N. (2020). Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal of Psychopharmacology, 34(2), 189–196. https://doi.org/10.1177/0269881119895536
Fundação Calouste Gulbenkian. (2016). Dossier O Cérebro e as Doenças Neurodegenerativas. Ciência em cena. https://content.gulbenkian.pt/wp-content/uploads/sites/16/2018/04/24100926/Dossie_2015_Neurodegenerativas.pdf
Fusar-Poli, P., Allen, P., Bhattacharyya, S., Crippa, J. A., Mechelli, A., Borgwardt, S., & McGuire, P. (2009). Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol. The International Journal of Neuropsychopharmacology, 13(04), 421. https://doi.org/10.1017/s1461145709990617
Giuliano, C., Francavilla, M., Ongari, G., Petese, A., Ghezzi, C., Rossini, N., Blandini, F., & Cerri, S. (2021). Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease. International Journal of Molecular Sciences, 22(16), 8920. https://doi.org/10.3390/ijms22168920
Gugliandolo, A., Pollastro, F., Bramanti, P., & Mazzon, E. (2020). Cannabidiol exerts protective effects in an in vitro model of Parkinson’s disease activating AKT/mTOR pathway. Fitoterapia, 143, Article 104553. https://doi.org/10.1016/j.fitote.2020.104553
Gustavsen, S., Sondergaard, H. B., Linnet, K., Thomsen, R., Rasmussen, B. S., Sorensen, P. S., Sellebjerg, F., & Oturai, A. B. (2021). Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis. Multiple Sclerosis and Related Disorders, 48, Article 102708. https://doi.org/10.1016/j.msard.2020.102708
Hughes, B., & Herron, C. E. (2019). Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease. Neurochemical Research, 44(3), 703–713. https://doi.org/10.1007/s11064-018-2513-z
Libro, R., Diomede, F., Scionti, D., Piattelli, A., Grassi, G., Pollastro, F., Bramanti, P., Mazzon, E., & Trubiani, O. (2016). Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells. International Journal of Molecular Sciences, 18(1). https://doi.org/10.3390/ijms18010026
Marchi, F. de, Contaldi, E., Magistrelli, L., Cantello, R., Comi, C., & Mazzini, L. (2021). Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians. Brain Sciences, 11(2), 237. https://dx.doi.org/10.3390/brainsci11020237
Marinus, J., Zhu, K., Marras, C., Aarsland, D., & van Hilten, J. J. (2018). Risk factors for non-motor symptoms in Parkinson’s disease. The Lancet Neurology, 17(6), 559–568. https://doi.org/10.1016/s1474-4422(18)30127-3
Moreno, J. L. L., Caldentey, J. G., Cubillo, P. T., Romero, C. R., Ribas, G. G., Arias, M. A. A., Yébenes, M. J. G., Tolón, R. M., Galve-Roperh, I., Sagredo, O., Valdeolivas, S., Resel, E., Ortega-Gutierrez, S., García-Bermejo, M. L., Ruiz, J. F., Guzmán, M., & Prous, J. G. Y. (2016). A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. Journal of Neurology, 263(7), 1390–1400. https://doi.org/10.1007/s00415-016-8145-9
Oliveira, M.T., & Paim, R.S. (2015). O uso terapêutico de canabinóides em pacientes portadores de doenças crônicas. III Congresso de Pesquisa e Extensão da FSG (pp. 825-827). Faculdade da Serra Gaúcha.
Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., Formaglio, F., Rossi, P., Clerici, M., Falzone, Y. M., Pozzi, L., Martinelli, D., Cerri, F., Lopez, I. D., Martinelli-Boneschi, F., & Quattrini, A. (2019). Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology, 18(2), 155–164. https://doi.org/10.1016/S1474-4422(18)30406-X
Sampieri, R. H., Collado, C. F., & Lucio, M. D. P. B. (2013). Metodologia de Pesquisa (5th ed). Penso.
Serra, I., Scheldeman, C., Bazelot, M., Whalley, B. J., Dallas, M. L., de Witte, P. A. M., & Williams, C. M. (2019). Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of Tuberous Sclerosis Complex. Behavioural Brain Research, 363, 135–144. https://doi.org/10.1016/j.bbr.2019.01.040
Sheikh, S., Safia, Haque, E., & Mir, S. S. (2013). Neurodegenerative Diseases: Multifactorial Conformational Diseases and Their Therapeutic Interventions. Journal of Neurodegenerative Diseases, 2013, Article 563481. https://doi.org/10.1155/2013/563481
Silva, L. M. G., Alencar, R. A., & Gomes Júnior, A. L. (2020). O potencial terapêutico e farmacológico do canabidiol. Research, Society and Development, 9(11), Article e2019119686. https://doi.org/10.33448/rsd-v9i11.9686
Silva, V. K., de Freitas, B. S., Garcia, R. C. L., Monteiro, R. T., Hallak, J. E., Zuardi, A. W., Crippa, J. A. S., & Schröder, N. (2018). Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload. Translational Psychiatry, 8(1). https://doi.org/10.1038/s41398-018-0232-5
Valdeolivas, S., Satta, V., Pertwee, R. G., Fernández-Ruiz, J., & Sagredo, O. (2012). Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB1 and CB2 Receptors. ACS Chemical Neuroscience, 3(5), 400–406. https://doi.org/10.1021/cn200114w
Vieira, A. R. M., Teixeira, L. H. de S., Santos, W. P. dos, Rosa, J. de J., Lopes, M. E., & Miceli, B. C. (2018). Um novo conceito para o tratamento de esclerose múltipla: Mevatil®. Revista Brasileira de Ciências Da Vida, 6 (Especial).
Vriend, C., Boedhoe, P. S., Rutten, S., Berendse, H. W., Werf, Y. D. van der, & Heuvel, O. A. van den. (2015). A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer—VBM study. Journal of Neurology, Neurosurgery & Psychiatry, 87(5), 493–500. https://doi.org/10.1136/jnnp-2015-310383
Ziemssen, T. (2019). Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence. Neurodegenerative Disease Management, 9(2), 1–2. https://doi.org/10.2217/nmt-2018-0048
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Ana Luiza Magalhães Silva; Ana Gabriela Hannum Noleto; Ana Laura Barra Borges; Bárbara da Costa Santana Borges; Giovanna Borges Magalhães; Luana Alves Simões; Rodrigo Scaliante de Moura
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
